TSE:VBV - VBI Vaccines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseC$4.82
Today's RangeC$4.82 - C$5.05
52-Week RangeC$3.85 - C$7.60
Volume1,300 shs
Average Volume3,637 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
Phone+1-617-8303031

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$872,000.00
Book ValueC$1.20 per share

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

VBI Vaccines (TSE:VBV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV."

Has VBI Vaccines been receiving favorable news coverage?

Headlines about VBV stock have been trending somewhat positive on Saturday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. VBI Vaccines earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future.

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
  • Dr. David Evander Anderson Ph.D., Chief Scientific Officer (Age 48)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Principal Financial & Accounting Officer, Chief Compliance Officer (Age 53)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 30)
  • Dr. Francisco Diaz-Mitoma M.D., Ph.D., Chief Medical Officer (Age 63)

How do I buy shares of VBI Vaccines?

Shares of VBV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is http://www.vbivaccines.com.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The company can be reached via phone at +1-617-8303031.


MarketBeat Community Rating for VBI Vaccines (TSE VBV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: What is Cost of Capital?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel